

**B. AMENDMENTS TO THE CLAIMS:**

Claims 1-6 and 45 have been cancelled without prejudice. Claims 7-44 and 46-54 have been withdrawn from consideration.

- 55. (New) A chimeric HPV L1 protein including at least one portion of HPV-18 L1 protein and at least one portion of HPV-45 L1 protein.
- 56. (New) The protein of Claim 55 wherein said protein includes at least the R5 epitope of HPV-18 L1 protein.
- 57. (New) The protein of Claim 56 wherein said protein includes at least amino acid residues 53 through 194 of HPV-18 L1 protein.
- 58. (New) The protein of Claim 57 wherein said protein includes at least amino acid residues 1-194 of HPV-18 L1 protein.
- 59. (New) The protein of Claim 58 wherein said protein includes amino acid residues 1-265 of HPV-18 L1 protein, amino acid residues 265-442 of HPV-45 L1 protein, and amino acid residues 443-507 of HPV-18 L1 protein.
- 60. (New) A method of treating a papillomavirus infection caused by at least one of HPV-18 and HPV-45 comprising administering to a patient an effective amount of the protein of Claim 55.